Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
290 6 |
Ultima descărcare din IBN: 2023-10-07 13:24 |
Căutarea după subiecte similare conform CZU |
616.23/24-002-036.12-085:577 (1) |
Patologie. Medicină clinică (6996) |
Bazele materiale ale vieții. Biochimie. Biologie moleculară. Biofizică (667) |
SM ISO690:2012 OBOROC, Sandu. New therapeutic targets in COPD treatment. In: Revista de Ştiinţe ale Sănătăţii din Moldova, 2022, nr. 3 An.1(29), p. 45. ISSN 2345-1467. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista de Ştiinţe ale Sănătăţii din Moldova | ||||||
Numărul 3 An.1(29) / 2022 / ISSN 2345-1467 | ||||||
|
||||||
CZU: 616.23/24-002-036.12-085:577 | ||||||
Pag. 45-45 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. The treatment of chronic obstructive pulmonary disease (COPD), currently limited to the use of bronchodilators, GCS and antibiotics, requires the expansion of therapeutic armamentarium that is closely linked to the widening of knowledge on the pathogenesis and evolution of COPD. Objective of the study. Elucidation of the groups and new perspective preparations in the treatment of chronic obstructive pulmonary disease. Material and methods. The PubMed database was analyzed to identify the groups and preparations of perspective in the treatment of COPD, using the keywords „COPD” and „new therapeutic targets”. Results. Research directions for preparations used in the treatment of COPD have been based on recently identified pathogenic mechanisms. The investigations focused on the development of new preparations from the GCS group (ciclesonide), β2-AM (indacaterol), M-CB (glicopironium), PDE inhibitors (roflumilast) and combined drugs. At the same time, new compounds were highlighted: dual-action M-CB and β2-AM antagonists (batefenterol), kinase inhibitors (imatinib), cytokine modifiers (mepolizumab), chemokine modifiers (plerixafor), NF-κB inhibitors, senolytics, antioxidants, inhaled antiviral agents, antifibrotic agents and stimulators of lung regeneration. Conclusion. The continuous knowledge expansion about the pathogenesis and evolution of COPD will lead to the identification of new therapeutic targets, potentially useful in the development of new preparations utilized in the treatment of COPD. |
||||||
Cuvinte-cheie COPD, new preparations, new compounds, new therapeutic targets, BPOC, preparate noi, compuși noi, ținte terapeutice noi |
||||||
|